---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-019768"
form_type: "8-K"
ticker: "BCPC"
cik: "0000009326"
company_name: "BALCHEM CORP"
filed_at: "2022-07-29T23:59:59+00:00"
generated_at: "2026-06-24T07:11:41.539076+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Balchem Q2 record net sales $236.7M (+17% YoY), GAAP EPS $0.92, adj. EPS $1.07

## Summary
- Record net sales $236.7M, up 17% YoY; GAAP EPS $0.92, adjusted EPS $1.07 (record).
- Adjusted EBITDA $56.5M, up 12.6% YoY; all three segments posted sales growth.
- Completed acquisition of Kappa (vitamin K2 manufacturer) on June 21, 2022; expands nutrition portfolio.
- Entered new $550M revolving credit facility due 2027, replacing $500M facility due 2023.
- Cash from operations $48.2M; net debt $357.4M, leverage ratio 1.8x.

## SEC filing metadata
- accession: 0001628280-22-019768
- form_type: 8-K
- ticker: BCPC
- cik: 0000009326
- company_name: BALCHEM CORP
- filed_at: 2022-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/9326/000162828022019768/0001628280-22-019768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/9326/000162828022019768/bcpc-20220729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-019768
- JSON: https://secwatch.observer/filing/0001628280-22-019768.json
- Plain text: https://secwatch.observer/filing/0001628280-22-019768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.